MX9701526A - Terapia combinada para tratar la osteoporosis. - Google Patents

Terapia combinada para tratar la osteoporosis.

Info

Publication number
MX9701526A
MX9701526A MX9701526A MX9701526A MX9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A
Authority
MX
Mexico
Prior art keywords
bone loss
parathyroid hormone
combination therapy
estrogen agonists
prevent bone
Prior art date
Application number
MX9701526A
Other languages
English (en)
Other versions
MXPA97001526A (es
Inventor
David B Maclean
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9701526A publication Critical patent/MX9701526A/es
Publication of MXPA97001526A publication Critical patent/MXPA97001526A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00107Coatings on the energy applicator
    • A61B2018/00148Coatings on the energy applicator with metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona nuevos procedimientos de tratar o prevenir la osteoporosis que comprenden administrar a un mamífero que necesite dicho tratamiento una cantidad eficaz de un compuesto de formula I en la que R1 y R2 pueden ser iguales o diferentes, con la condicion de que cuando R1 y R2 son iguales, cada uno es un grupo metilo o etilo y cuando R1 y R2 son diferentes, uno de ellos es un grupo metilo o etilo y el otro es hidrogeno o un grupo bencilo; o una sal farmacéuticamente aceptable del mismo; junto con un polifosfanato inhibidor de la resorcion osea, o hormona paratiroidea.
MXPA/A/1997/001526A 1996-02-28 1997-02-27 Terapia combinada para tratar la osteoporosis MXPA97001526A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US012409 1987-02-09
US1239996P 1996-02-28 1996-02-28
US1240996P 1996-02-28 1996-02-28
US012399 1996-02-28

Publications (2)

Publication Number Publication Date
MX9701526A true MX9701526A (es) 1998-06-28
MXPA97001526A MXPA97001526A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
EP0792639A1 (en) 1997-09-03
AU1497897A (en) 1997-09-04
US5773477A (en) 1998-06-30
ZA971711B (en) 1998-08-27
US5861438A (en) 1999-01-19
CA2198580A1 (en) 1997-08-28
CN1166316A (zh) 1997-12-03
JPH09328430A (ja) 1997-12-22
KR970061249A (ko) 1997-09-12
IL120270A0 (en) 1997-06-10
AU718242B2 (en) 2000-04-13
CA2198580C (en) 2001-07-03

Similar Documents

Publication Publication Date Title
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
CA2245142A1 (en) New phenanthridines
MY119403A (en) Novel compounds with analgesic effect.
CA2198535A1 (en) Method of increasing testosterone
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
AP2002002458A0 (en) Compounds for the treatment of ischemia.
PL347671A1 (en) Compounds and compositions for delivering active agents
ZA935943B (en) New formulations
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
EP0938317A4 (en) COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION
CA2198580A1 (en) Combination therapy to treat osteoporosis
TW324662B (en) Benzamide-containing pharmaceutical composition
NO984920L (no) Preparater omfattende en nitronforbindelse for anvendelse ved behandling av okulµr inflammasjon
MX9709466A (es) Medicamento para inhibir el melanoma.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
EP0476711A3 (en) Use of 5-fluorouracil for the treatment of AIDS
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
AU4944899A (en) New pharmaceutically active compounds
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.